Competitive AdvantageThe dose expansion part of the AUDIOGENE study could be pivotal in the EU, providing a competitive advantage over other studies that only measure safety.
Safety And EfficacySensorion announced a data update confirming the safety of its lead gene therapy asset, SENS-501, in the first two patients injected in the company's Audiogene study.
Therapeutic PotentialSENS-501 could enable better restoration of auditory brainstem response and speech capacities by treating very young patients.